UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 589

Sortiert nach

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

The lancet oncology, 2014-11, Vol.15 (12), p.1389-1396

2014

Volltextzugriff (PDF)

Volar location and degree of pigmentation are associated with poor survival and first metastasis pattern in acral melanoma

Pigment cell and melanoma research, 2021-11, Vol.34 (6), p.1094-1104

2021

Volltextzugriff (PDF)

Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients

World journal of gastroenterology : WJG, 2021-11, Vol.27 (42), p.7340-7349

2021

Volltextzugriff (PDF)

Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer

Cancer science, 2020-09, Vol.111 (9), p.3268-3278

2020

Volltextzugriff (PDF)

Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

Cancer, 2020-10, Vol.126 (20), p.4521-4531

2020

Volltextzugriff (PDF)

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021, Vol.24 (1), p.156-167

2021

Volltextzugriff (PDF)

Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy

Scientific reports, 2020-06, Vol.10 (1), p.9549-9549, Article 9549

2020

Volltextzugriff (PDF)

A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma

Frontiers in immunology, 2022-06, Vol.13, p.879452-879452

2022

Volltextzugriff (PDF)

The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers

Molecular carcinogenesis, 2015-10, Vol.54 (10), p.1172-1180

2015

Volltextzugriff (PDF)

Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma

International journal of oncology, 2019-08, Vol.55 (2), p.513-526

2019

Volltextzugriff (PDF)

Trogocytic molting of T cell microvilli upregulates T cell receptor surface expression and promotes clonal expansion

Nature communications, 2023-05, Vol.14 (1), p.2980-2980, Article 2980

2023

Volltextzugriff (PDF)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

The lancet oncology, 2012-11, Vol.13 (11), p.1125-1132

2012

Volltextzugriff (PDF)

Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis

Frontiers in oncology, 2023-10, Vol.13, p.1265240-1265240

2023

Volltextzugriff (PDF)

Gal-3BP Negatively Regulates NF-κB Signaling by Inhibiting the Activation of TAK1

Frontiers in immunology, 2019-07, Vol.10, p.1760-1760

2019

Volltextzugriff (PDF)

Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer

Biomaterials, 2013-01, Vol.34 (4), p.1433-1441

2013

Volltextzugriff (PDF)

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)

Cancer medicine (Malden, MA), 2023-04, Vol.12 (7), p.7784-7794

2023

Volltextzugriff (PDF)

Does awareness of terminal status influence survival and quality of life in terminally ill cancer patients?

Psycho-oncology (Chichester, England), 2013-10, Vol.22 (10), p.2206-2213

2013

Volltextzugriff (PDF)

Full-blown hyperparathyroidism

The Korean Journal of Internal Medicine, 2018, 33(6), , pp.1258-1259

2018

Volltextzugriff (PDF)

Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy

Journal of hematology and oncology, 2021-03, Vol.14 (1), p.43-43, Article 43

2021

Volltextzugriff (PDF)

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Cancer science, 2010-05, Vol.101 (5), p.1247-1254

2010

Volltextzugriff (PDF)

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

BMC cancer, 2011-11, Vol.11 (1), p.489-489, Article 489

2011

Volltextzugriff (PDF)

Lgals3bp suppresses colon inflammation and tumorigenesis through the downregulation of TAK1-NF-κB signaling

Cell death discovery, 2021-04, Vol.7 (1), p.65-13, Article 65

2021

Volltextzugriff (PDF)

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin

Science translational medicine, 2017-02, Vol.9 (376)

2017

Volltextzugriff (PDF)

Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy

Japanese journal of clinical oncology, 2015-06, Vol.45 (6), p.541-546

2015

Volltextzugriff (PDF)

1 – 25 von 589

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(555)
Mit Volltextzugriff
(562)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

Volar location and degree of pigmentation are associated with poor survival and first metastasis pattern in acral melanoma

Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients

Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer

Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Observational Study of Peritoneal Washing Cytology-Positive Gastric Cancer without Gross Peritoneal Metastasis in Patients who Underwent Radical D2 Gastrectomy

A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma

The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers

Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma

Trogocytic molting of T cell microvilli upregulates T cell receptor surface expression and promotes clonal expansion

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis

Gal-3BP Negatively Regulates NF-κB Signaling by Inhibiting the Activation of TAK1

Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)

Does awareness of terminal status influence survival and quality of life in terminally ill cancer patients?

Full-blown hyperparathyroidism

Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

Lgals3bp suppresses colon inflammation and tumorigenesis through the downregulation of TAK1-NF-κB signaling

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin

Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy

Suchergebnisse filtern